Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 26/202
Respiratory System 5/53
Impact Factor: 5.800
Editor's Choice

Four manuscripts are highlighted in the April issue of JTO. The first manuscript, “The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung” by Gazdar et al provides an excellent overview of GEMMs and is accompanied by an insightful editorial by Dr Takashi Kohno. The second article is High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma by Carbone et al. This manuscript provides useful information on this common mutation in mesothelioma. The manuscript on ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice by Martin et al , is accompanied by an editorial by Dr Yasushi Yatabe. The last article, “Modified Masaoka Stage and Size Are Independent Prognostic Predictors in Thymoma and Modified Masaoka Stage is Superior to Histopathologic Classifications” by Roden et al addresses the issue of classification for thymoma and prognosis. Alex A. Adjei, MD, PhD, Editor-in-Chief

Actions
View
  • Open Access
  • Free Access
  • Purchase Access
  • Partial Access
Actions
View
Login

Quick Poll

For coverage of this subject, please see Boland JM et al, J Thorac Oncol, 8: 574 -581, 2013

A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 

Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.